Treatment of Advanced, Unresectable or Metastatic Mucosal Melanoma with BRAF V600 Mutation
A subset of mucosal melanoma cases harbour a BRAF V600 mutation, which defines a distinct clinical scenario in advanced or metastatic disease — one for which a specific targeted treatment strategy is supported by phase III evidence.
Clinical scenario: BRAF V600 mutations occur in approximately 12% of mucosal melanomas. When identified in a patient with advanced, unresectable, or metastatic disease, this mutation signals eligibility for a targeted therapeutic approach separate from standard immunotherapy-based strategies.
Treatment approach: The evidence-based regimen for this setting involves targeted therapy combining a BRAF inhibitor with a MEK inhibitor. Phase III data show that this dual-inhibition strategy produces meaningful improvements in survival outcomes compared to monotherapy. The complete protocol — including specific agents, sequencing, and clinical parameters — is available via the link below.
References
DOI: 10.1200/EDBK-25-473858
MM has a BRAF V600 mutation rate of approximately 12% and may also be benefited from it.
A phase III clinical trial enrolled 423 patients with advanced BRAF V600-mutant melanoma to evaluate the safety and efficacy of combination therapy with a BRAFi and a MEKi (dabrafenib monotherapy v dabrafenib plus trametinib).
The combination therapy significantly improved PFS and OS.
View source ↗